Company news

TriSalus Life Sciences, Inc. news in 2024

TriSalus Life Sciences, Inc.'s news releases, calls and decks from 2024, newest first.

View company

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

November 13, 2024

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

November 10, 2024

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

November 6, 2024

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

October 30, 2024

TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

October 13, 2024

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

September 25, 2024

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

September 22, 2024

TriSalus Reports Q2 2024 Financial Results and Business Update

August 14, 2024

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

July 31, 2024

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

June 30, 2024

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

June 25, 2024

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

June 2, 2024

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

May 23, 2024

TriSalus Reports Q1 2024 Financial Results and Business Update

May 14, 2024

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

May 6, 2024

TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call

May 5, 2024

TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives

April 29, 2024

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

March 31, 2024

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

March 25, 2024

TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting

March 20, 2024

TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results

March 10, 2024

TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101

March 6, 2024

TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors

February 28, 2024

Calls in 2024

Decks in 2024